Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1678-1683, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (88)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertina, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertina, R. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Oak Ridge Conference
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 1997;43:1678-1683.)
© 1997 American Association for Clinical Chemistry, Inc.

Oak Ridge Conference

Factor V Leiden and other coagulation factor mutations affecting thrombotic risk

Rogier M. Bertina

Hemostasis and Thrombosis Research Center, Leiden University Medical Center, C2-R-143, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Fax +31-71-5266755; e-mail Bertina{at}rullf2.leidenuniv.nl


Abstract

Five genetic defects have been established as risk factors for venous thrombosis. Three are protein C, protein S, and antithrombin deficiencies, defects in the anticoagulant pathways of blood coagulation. Together they can be found in ~15% of families with inherited thrombophilia. Their laboratory diagnosis is hampered by the large genetic heterogeneity of these defects. The other two genetic risk factors, resistance to activated protein C associated with the factor V Leiden mutation and increased prothrombin associated with the prothrombin 20210 A allele, are much more prevalent and together can be found in 63% of the thrombophilia families. Because both defects are caused by a single mutation, DNA analysis is the basis of their laboratory diagnosis.




The following articles in journals at HighWire Press have cited this article:


Home page
 BloodHome page
B. Dahlback
Advances in understanding pathogenic mechanisms of thrombophilic disorders
Blood, July 1, 2008; 112(1): 19 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Bortolin, M. Black, H. Modi, I. Boszko, D. Kobler, D. Fieldhouse, E. Lopes, J.-M. Lacroix, R. Grimwood, P. Wells, et al.
Analytical Validation of the Tag-It High-Throughput Microsphere-Based Universal Array Genotyping Platform: Application to the Multiplex Detection of a Panel of Thrombophilia-Associated Single-Nucleotide Polymorphisms
Clin. Chem., November 1, 2004; 50(11): 2028 - 2036.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
M. Patnaik, J. S. Dlott, R. N. Fontaine, M.T. Subbiah, M. J. Hessner, K. A. Joyner, M. R. Ledford, E. C. Lau, C. Moehlenkamp, J. Amos, et al.
Detection of Genomic Polymorphisms Associated with Venous Thrombosis Using the Invader Biplex Assay
J. Mol. Diagn., May 1, 2004; 6(2): 137 - 144.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Dahm, A. van Hylckama Vlieg, B. Bendz, F. Rosendaal, R. M. Bertina, and P. M. Sandset
Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
Blood, June 1, 2003; 101(11): 4387 - 4392.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Erali, B. Schmidt, E. Lyon, and C. Wittwer
Evaluation of Electronic Microarrays for Genotyping Factor V, Factor II, and MTHFR
Clin. Chem., May 1, 2003; 49(5): 732 - 739.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
S. Huber, K. J. McMaster, and K. V. Voelkerding
Analytical Evaluation of Primer Engineered Multiplex Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for Detection of Factor V Leiden and Prothrombin G20210A
J. Mol. Diagn., August 1, 2000; 2(3): 153 - 157.
[Abstract] [Full Text]

Home page
 CLIN APPL THROMB HEMOSTHome page
Y. Mira, J. Aznar, A. Estelles, A. Vaya, P. Villa, and F. Ferrando
State-of-the-Art Review : Congenital and Acquired Thrombotic Risk Factors in Women Using Oral Contraceptives: Clinical Aspects
Clinical and Applied Thrombosis/Hemostasis, July 1, 2000; 6(3): 162 - 168.
[Abstract] [PDF]

Home page
 BloodHome page
A. v. H. Vlieg, I. K. van der Linden, R. M. Bertina, and F. R. Rosendaal
High levels of factor IX increase the risk of venous thrombosis
Blood, June 15, 2000; 95(12): 3678 - 3682.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
H. Ioannou, A. Eleftheriou, V. Nousias, C. Basioukas, G. Kakosimos, C. Batsis, G. Vartholomatos, and M. Mitsis
Combined Genetic Defect (Homogeneity for Factor V Leiden and Heterogeneity for Prothrombin G20210A Allele), in a Young Patient, with Recurrent Deep Vein Thrombosis and Serious Postphlebitic Syndrome: A Case Report
Angiology, April 1, 2000; 51(4): 325 - 329.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
N. von Ahsen, E. Schutz, V. W. Armstrong, and M. Oellerich
Rapid Detection of Prothrombotic Mutations of Prothrombin (G20210A), Factor V (G1691A), and Methylenetetrahydrofolate Reductase (C677T) by Real-Time Fluorescence PCR with the LightCycler
Clin. Chem., May 1, 1999; 45(5): 694 - 696.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. O. Burdick and R. M. Bertina
Thrombotic Risks: A Clarification
Clin. Chem., July 1, 1998; 44(7): 1580 - 1580.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.